Neoadjuvant Serplulimab with S-1 Plus Oxaliplatin Followed by Adjuvant Serplulimab Significantly Improves EFS in PD-L1-positive, Resectable Gastric or GEJ Adenocarcinoma By Ogkologos - June 30, 2026 46 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ASTRUM-006 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR The Barriers to Care Faced by LGBTQ People With Cancer: An... January 21, 2021 New chemotherapy-free treatment for bowel cancer made available in Scotland September 14, 2021 For Older Adults, Geriatric Assessment Reduces Cancer Treatment Side Effects December 15, 2021 Ultra-Low-Dose Nivolumab Significantly Improves OS Over Chemotherapy in Pretreated Patients with... February 17, 2026 Load more HOT NEWS Coming together for Zynlonta EMA Recommends Extension of Indications for Sugemalimab Doctors Seem To Be Biased Against Unmarried Cancer Patients, Offer Them... ALK Mutations and Amplifications are Independent Predictors of Poorer Survival in...
